In yesterday's NEJM, the results of two trials of antiamyloid monoclonal antibodies (sonalezumab and bapeneuzumab) for Alzheimer's Disease (AD) are published. I became interested in the evidence for AD treatments after the recent trial of Vitamin E and Mematine for AD (the TEAM-AD VA Cooperative Trial) was published in JAMA earlier this month. Regular readers know that I think that the prior probability that vitamins, minerals, and antioxidants are beneficial for any disease outside of deficiency states is very low. The vitamin E trial was the impetus for some background investigation which I will summarize below.
